A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Oncotarget
Wu, Lina L; Yao, Lu L; Zhang, Hong H; Ouyang, Tao T; Li, Jinfeng J; Wang, Tianfeng T; Fan, Zhaoqing Z; Fan, Tie T; Lin, Benyao B; Yin, C Cameron CC; Xie, Yuntao Y